This trial is testing paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide to see if it is effective in treating patients with breast cancer.
1 Primary · 8 Secondary · Reporting Duration: up to 10 years
Active Control
Experimental Treatment
454 Total Participants · 4 Treatment Groups
Primary Treatment: Bevacizumab · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: